Admedus Ltd

ABN 35 088 221 078

5 December 2016

Centralised Company Announcements Platform Australian Stock Exchange

10th floor, 20 Bond Street Sydney NSW 2000

Dear Sir / Madam,

Appendix 3B - Share Issue

REGISTERED OFFICE:

26 Harris Road Malaga Western Australia 6090

PO Box 6879

East Perth Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info.au@admedus.com www.admedus.com

The Board of Directors of Admedus Ltd hereby announces that the Company has completed a one and only allotment of 3,000,000 ordinary fully paid shares (to be held in escrow for a period of 12 months from the date of issue) pursuant to a confidential settlement of legal proceedings as announced on 9 September 2016 which resulted in the Company owning 100% of Admedus' regenerative tissue technology.

Refer to the attached Appendix 3B.

Yours sincerely

For and on behalf of Admedus Limited Maja McGuire Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

ADMEDUS LIMITED

ABN

35 088 221 078

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1

+Class of +securities issued or to be issued

Ordinary fully paid shares

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

3,000,000

3

Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid

+securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Ordinary fully paid shares ranking equally with existing shares.

The shares will be released from escrow 12 months after the date on which they were issued.

4

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

  • the date from which they do

  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes

5

Issue price or consideration

Nil monetary consideration.

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

Issued pursuant to a confidential settlement of the legal proceedings as announced on 9 September 2015 which resulted in the Company owning 100% of Admedus' regenerative tissue technology.

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

Yes

6b

The date the security holder resolution under rule 7.1A was passed

10 November 2016

6c

Number of +securities issued without security holder approval under rule 7.1

N/A

6d

Number of +securities issued with security holder approval under rule 7.1A

N/A

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

N/A

6f

Number of securities issued under an exception in rule 7.2

N/A

6g

If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

N/A

6h

If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

Listing Rule 7.1 capacity: 34,760,204 Listing Rule 7.1A capacity: 25,173,469

7

Dates of entering +securities into uncertificated holdings or despatch of certificates

1 December 2016

Number

+Class

8

Number and +class of all

+securities quoted on ASX (including the securities in section 2 if applicable)

254,734,693

Ordinary Shares

Admedus Ltd. published this content on 05 December 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 December 2016 02:28:08 UTC.

Original documenthttp://clients2.weblink.com.au/clients/admedus/article.asp?asx=AHZ&view=6802487

Public permalinkhttp://www.publicnow.com/view/2AAC16D365E1453B384C0CDB5E03E2A1C771A869